TRVN Stock Overview A biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. More details
Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Trevena, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Trevena Historical stock prices Current Share Price US$1.80 52 Week High US$19.23 52 Week Low US$1.13 Beta 1.04 1 Month Change 7.14% 3 Month Change -53.85% 1 Year Change -89.79% 3 Year Change -99.53% 5 Year Change -99.66% Change since IPO -99.96%
Recent News & Updates
Trevena, Inc. Appoints Katrine Sutton as Principal Financial Officer and Principal Accounting Officer Nov 28
Trevena, Inc.(OTCPK:TRVN) dropped from S&P TMI Index Oct 10
Trevena, Inc.(OTCPK:TRVN) dropped from NASDAQ Composite Index Oct 08
Trevena Announces Receipt of Nasdaq Delisting Notification Oct 05
Trevena Regains Compliance with the Minimum Bid Price Requirement from Nasdaq Aug 31
New major risk - Share price stability Aug 19 See more updates
Trevena, Inc. Appoints Katrine Sutton as Principal Financial Officer and Principal Accounting Officer Nov 28
Trevena, Inc.(OTCPK:TRVN) dropped from S&P TMI Index Oct 10
Trevena, Inc.(OTCPK:TRVN) dropped from NASDAQ Composite Index Oct 08
Trevena Announces Receipt of Nasdaq Delisting Notification Oct 05
Trevena Regains Compliance with the Minimum Bid Price Requirement from Nasdaq Aug 31
New major risk - Share price stability Aug 19
New major risk - Revenue and earnings growth Aug 11
Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.69 loss in 2Q 2023) Aug 09
Trevena, Inc. Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models Jun 21
First quarter 2024 earnings released: US$0.36 loss per share (vs US$0.81 loss in 1Q 2023) May 17
Nasdaq Hearings Panel Grants Trevena an Extension Until August 28, 2024 to Regain Compliance with the Nasdaq Continued Listing Requirements, Including the Minimum Bid Price Requirement and Equity Standard Requirement May 16
Trevena, Inc., Annual General Meeting, Jun 13, 2024 May 01
New major risk - Revenue and earnings growth Apr 02
Full year 2023 earnings: EPS and revenues miss analyst expectations Apr 01
No longer forecast to breakeven Apr 01
New major risk - Market cap size Feb 06
Trevena, Inc. Promotion of Barry Shin to the Position of Executive Vice President and Chief Operating Officer Feb 01
Trevena, Inc. announced that it expects to receive $1.945934 million in funding Dec 29
Trevena, Inc. announced that it expects to receive $1.945934 million in funding Dec 28 Trevena, Inc. announced that it expects to receive $1.945934 million in funding Dec 27
Trevena, Inc. Announces Acceptance of Abstract Examining the Use of Olinvyk in Patients with Acute Burn Injuries Dec 01
New major risk - Revenue and earnings growth Nov 17
Consensus EPS estimates fall by 28%, revenue upgraded Nov 16
Trevena, Inc. Announces Board Changes Nov 12
Trevena, Inc. to Report Q3, 2023 Results on Nov 14, 2023 Nov 10
New major risk - Revenue and earnings growth Oct 25
Trevena, Inc. Announces Completion of Initial Analysis of Olinvyk Continuous Respiratory Monitoring Data from Volition Study Oct 05
Trevena, Inc. Announces Retirement of Michael Dougherty as A Member of the Board of Directors and as A Member of the Audit Committee, Effective as of September 14, 2023 Sep 20
Trevena, Inc. Announces Preliminary TRV045 Data from Two Proof-Of-Concept Studies Evaluating S1pr Mechanism of Action and CNS Target Engagement Sep 07
Trevena Receives Non-Compliance Notice From Nasdaq Stock Market Sep 02
Consensus revenue estimates increase by 725% Aug 21
New major risk - Market cap size Aug 11
Trevena, Inc. Appoints Mark Corrigan to Board of Directors Jul 23
Trevena, Inc. Announces New Topline OLINVYK Data Highlighting Reduced Cost Per Admission from Artemis Real-World Outcomes Study Jun 27
New major risk - Market cap size Jun 21
Trevena Regains Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2) May 31 Trevena, Inc. to Report Q1, 2023 Results on May 15, 2023
Price target decreased by 39% to US$17.00 May 10
Trevena Announces Publication of OLINVYK Respiratory Physiology Study in ANESTHESIOLOGY Feb 15
Trevena, Inc. Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement Jan 10
Trevena Regains Compliance with Nasdaq Listing Requirements Nov 30
Price target decreased to US$28.67 Nov 23
Insufficient new directors Nov 16
Trevena Announces Completion of Phase 1 Study for Trv045, Novel S1p Receptor Modulator Nov 10
Trevena, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Nov 08
Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting Oct 25
Consensus forecasts updated Aug 18
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 12
Trevena Q2 2022 Earnings Preview Aug 10
Trevena, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 09
Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update Jul 29
Trevena slides on $2M preferred stock offering Jul 29
Trevena (NASDAQ:TRVN) Will Have To Spend Its Cash Wisely Jul 08
Trevena Gets an Additional 180 Days to Get Listing Compliance Jun 22
Consensus revenue estimates fall by 36% May 18
First quarter 2022 earnings: EPS and revenues miss analyst expectations May 13 Trevena, Inc., Annual General Meeting, Jun 09, 2022
Insufficient new directors Apr 27
Trevena, Inc. Receives Notice to Cease Enrollment for TRV027 as Part of the ACTIV-4 Host Tissue Platform Apr 26 Trevena, Inc. Announces Results from Pfound D Sedation, Respiratory Depression, Coma, and Death May Result from E Concomitant Use of Olinvyk
Consensus forecasts updated Apr 07
Trevena, Inc. to Report Q4, 2021 Results on Mar 31, 2022 Mar 31
Is Trevena (NASDAQ:TRVN) In A Good Position To Deliver On Growth Plans? Mar 19
Price target decreased to US$4.67 Mar 05
Insufficient new directors Mar 05
Trevena, Inc. Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical Jan 28
Trevena, Inc. Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain Dec 14
Trevena Offers An Enticing Risk-Reward At These Prices Dec 14
Trevena Announces Wake Forest Baptist Health Joining OLINVYK® Clinical Outcomes Study Aug 26
Trevena: Remaining Patient After A Disappointing Q2 Earnings Aug 17
Trevena Announces Publication of OLINVYK® Health Economic Model in Journal of Comparative Effectiveness Research Jul 14
Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder Jun 17
Trevena announces resumption of NIH-run trial for TRV734 in opioid use disorder Jun 16
Trevena, Inc. Announces Presentation of OLINVYK® Respiratory Safety Data in High-Risk Patients at the 46th Annual ASRA Meeting May 13
Trevena's OLINVYK Provides One Of The Most Compelling Growth Profiles May 10
Trevena Investor Presentation - Slideshow May 08
Trevena, Inc. Announces TRV027 Selected by NIH-Funded ACTIV Initiative for COVID-19 Trial May 07
Trevena, Inc. Announces Board Changes Mar 19
Trevena, Inc. to Report Q4, 2020 Results on Mar 09, 2021 Mar 06
Trevena, Inc. Publishes New Analysis of Respiratory Safety Data from the OLINVYK Phase 3 Multi-Site Jan 29
Trevena, Inc. Provides Update on Commercial Launch Activities for OLINVYK and Announces Anticipated Pipeline Catalysts Jan 08
Trevena, Inc. Announces Publication Highlighting GI Tolerability Profile of OLINVYK™ (oliceridine) Injection in Pain and Therapy Nov 21
Trevena (TRVN) Investor Presentation - Slideshow Nov 16
Trevena: Reaffirming A Buy On OLINVYK DEA Scheduling Nov 09
Trevena, Inc. Announces DEA Scheduling of OLINVYK™ (Oliceridine) Injection Nov 02
DEA classifies Trevena's oliceridine, distribution to start in November Oct 30
Trevena, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million. Aug 13 Shareholder Returns TRVN US Biotechs US Market 7D 2.9% -3.3% -0.4% 1Y -89.8% -2.7% 24.8%
See full shareholder returns
Return vs Industry: TRVN underperformed the US Biotechs industry which returned -1.9% over the past year.
Return vs Market: TRVN underperformed the US Market which returned 23.9% over the past year.
Price Volatility Is TRVN's price volatile compared to industry and market? TRVN volatility TRVN Average Weekly Movement 24.1% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: TRVN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TRVN's weekly volatility has increased from 18% to 24% over the past year.
About the Company Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Show more Trevena, Inc. Fundamentals Summary How do Trevena's earnings and revenue compare to its market cap? TRVN fundamental statistics Market cap US$1.36m Earnings (TTM ) -US$34.04m Revenue (TTM ) US$546.00k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) TRVN income statement (TTM ) Revenue US$546.00k Cost of Revenue US$1.59m Gross Profit -US$1.04m Other Expenses US$33.00m Earnings -US$34.04m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -39.40 Gross Margin -190.48% Net Profit Margin -6,233.70% Debt/Equity Ratio -141.0%
How did TRVN perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 09:57 End of Day Share Price 2024/12/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Trevena, Inc. is covered by 17 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Difei Yang Aegis Capital Corporation Ying Huang Barclays Jonathan Aschoff Brean Capital
Show 14 more analysts 
